Abstract
Tuberculosis and bacterial infections are major challenges because of elevated infection rates and drug resistance. New chemical agents need to be developed to address them. Thiolactomycin and quinolines are promising lead molecules in the design of new antitubercular and antibacterial agents. Herein, we report the design and synthesis of series of new quinoline-thiolactone conjugates as potential antitubercular and antibacterial agents. Two of the conjugates, 6b and 6d, exhibited good antitubercular activity with MIC value of 8 µg/mL. Docking studies showed that the conjugates, 6b and 6d, exhibited good binding affinity towards the target protein KasA of M. tuberculosis. Two other conjugates also showed decent antibacterial activity with MIC value of 8 µg/mL. Further, the docking of conjugate 7a was better than standard drug, linezolid against three different molecular receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
